Riskpilot← Back to searchSign inGet full accessMedivia Aktiebolag
ABActiveOrg 5563422293Kammakargatan 11 1trMedical specialists activities · NACE 8622Est. 19880 employees
Revenue 2025
SEK 2K
-95% vs 2024
EBITDA margin
-2859.0%
-867% vs 2024
Equity ratio
30.4%
Financial strength
Net profit 2025
SEK -60K
-1076% vs 2024
| Revenue | SEK 2K | -95% |
| EBITDA | SEK -60K | -867% |
| Net profit | SEK -60K | -1076% |
| Total assets | SEK 145K | -31% |
| Equity | SEK 44K | -58% |
| Employees | 0 | — |
Legal name
Medivia Aktiebolag
Org number
5563422293
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
29 november 1988
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktie bolaget ska bedriva läkarmottagning, film- och videopro- duktion, utbildning och konsultverksamhet inom medicin och psykiatri, äga och förvalta fastigheter och värdepapper, bedriva konsult- och produktionsverksamhet inom data och informations- teknologi och därmed förenlig verksamhet.
Address
Kammakargatan 11 1tr
Phone
+468310810
Email
rg@medivia.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 969 | 721 | 202 | 47 | 2 |
| Staff expenses | — | −469 | −88 | −2 | −9 |
| EBITDA | 213 | 182 | 45 | 8 | −60 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 213 | 182 | 45 | 8 | −60 |
| Net financials | −1 | −0 | 0 | 0 | — |
| Profit before tax | 212 | 182 | 46 | 8 | −60 |
| Tax | −44 | −38 | −9 | −2 | — |
| Net profit | 168 | 144 | 36 | 6 | −60 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 556 | 449 | 243 | 209 | 145 |
| Equity | 278 | 262 | 98 | 104 | 44 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 279 | 187 | 145 | 105 | 101 |
| Total debt | 279 | 187 | 145 | 105 | 101 |
EBITDA margin
-2859.0%
This company
15.8%
Market median
-18195% vs market
20212025
Equity ratio
30.4%
This company
38.2%
Market median
+20% vs market
20212025
Return on equity
-136.6%
This company
18.4%
Market median
-842% vs market
20212025
Net profit margin
-2859.0%
This company
8.1%
Market median
-35396% vs market
20212025
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20212025
Debt / equity
2.28×
This company
0.62×
Market median
-268% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medivia Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Henry Glant | Chairman | 0 companies |
| Jan Oliver Simon Glant | Deputy Board Member | 0 companies |
| Sigrid Anna Helene Glant | Board of Directors | 0 companies |
| Max Robert Molvidson | Deputy Board Member | 0 companies |